We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 14, 2021

Patients Considering Natalizumab for MS Overestimate Risk for Progressive Multifocal Leukoencephalopathy

International Journal of MS Care


Additional Info

Disclosure statements are available on the authors' profiles:

International Journal of MS Care
Progressive Multifocal Leukoencephalopathy Risk Perception in Patients Considering Natalizumab for Multiple Sclerosis
Int J MS Care 2021 May 08;[EPub Ahead of Print], R Berkovich, J Eskenazi, A Yakupova, EL Riddle

Further Reading